Wall Street analysts expect Juno Therapeutics, Inc. (NASDAQ:JUNO) to report $17.18 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Juno Therapeutics’ earnings, with estimates ranging from $15.00 million to $20.00 million. Juno Therapeutics posted sales of $27.60 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 37.8%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 3rd.
On average, analysts expect that Juno Therapeutics will report full-year sales of $17.18 million for the current fiscal year, with estimates ranging from $57.00 million to $79.33 million. For the next year, analysts expect that the company will report sales of $82.71 million per share, with estimates ranging from $50.00 million to $161.85 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Juno Therapeutics.
Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. Juno Therapeutics had a negative net margin of 288.66% and a negative return on equity of 24.57%. The company had revenue of $19.30 million during the quarter, compared to the consensus estimate of $16 million. During the same quarter in the previous year, the company earned ($0.78) earnings per share. The business’s revenue was up 96.9% on a year-over-year basis.
Several research firms have recently issued reports on JUNO. Vetr raised Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $25.42 target price on the stock in a research note on Tuesday, March 21st. Wedbush reissued a “neutral” rating and set a $24.00 target price on shares of Juno Therapeutics in a research note on Friday, May 5th. Morgan Stanley reduced their target price on Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, May 8th. Citigroup Inc. reduced their target price on Juno Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, April 4th. Finally, FBR & Co reissued a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. Juno Therapeutics currently has a consensus rating of “Buy” and an average target price of $30.81.
In other news, CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the transaction, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at $22,085,670. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley purchased 20,000 shares of the stock in a transaction dated Friday, May 26th. The shares were acquired at an average cost of $24.76 per share, for a total transaction of $495,200.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 8,041,500 shares of company stock worth $217,230,360. Corporate insiders own 15.26% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in JUNO. Canada Pension Plan Investment Board boosted its stake in Juno Therapeutics by 111.2% in the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock worth $2,095,000 after buying an additional 49,700 shares during the period. Wells Fargo & Company MN boosted its stake in Juno Therapeutics by 238.4% in the first quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 85,516 shares during the period. Nisa Investment Advisors LLC purchased a new stake in Juno Therapeutics during the first quarter worth approximately $200,000. Creative Planning boosted its stake in Juno Therapeutics by 248.8% in the first quarter. Creative Planning now owns 48,016 shares of the biopharmaceutical company’s stock worth $1,065,000 after buying an additional 34,250 shares during the period. Finally, Opus Point Partners Management LLC boosted its stake in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 4,560 shares during the period. 64.51% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Juno Therapeutics (NASDAQ JUNO) traded up 2.17% during mid-day trading on Wednesday, reaching $28.22. The company had a trading volume of 1,128,079 shares. The firm’s market capitalization is $2.94 billion. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $35.04. The stock has a 50 day moving average price of $26.33 and a 200 day moving average price of $23.51.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
